Report to Congress Identifies Significant Implications of Marijuana Rescheduling


On September 13, 2023, the Congressional Research Service (CRS) released a report prepared for members of Congress regarding the recent recommendation by the Department of Health and Human Services (HHS) that marijuana be rescheduled from Schedule 1 to Schedule 3 under the Controlled Substances Act (CSA).

The recommendation by HHS was based on a review performed by the Food and Drug Administration (FDA) pursuant to the executive order of President Biden issued in October 2022. The Drug Enforcement Agency (DEA) will now conduct its own review.

DEA Approval Is Likely
As a result of the DEA’s acknowledgment during a 2020 congressional hearing that it is “bound by FDA’s recommendations on scientific and medical matters,” the CRS report predicts that “if past is prologue it could be likely that DEA will reschedule marijuana according to HHS's recommendation.” This is because “CRS is unaware of any instance where DEA has rejected an FDA recommendation to reschedule.”

State Policy Implications
The CRS report states that when marijuana is likely rescheduled to Schedule 3, it will have significant implications for state medical marijuana programs, but fewer implications for state adult-use programs. “A move to any lower schedule would allow for medical use of marijuana while maintaining federal criminal control over marijuana pursuant to the CSA.”

Federal Policy Implications
Several federal policy implications of rescheduling marijuana are identified by CRS, including:

Options for Congress
Finally, CRS emphasizes that Congress may choose to act with respect to the rescheduling of marijuana. This could include legislation to place marijuana on one of the other schedules under the CSA, create a separate classification for marijuana under the CSA or remove marijuana as a controlled substance altogether. CRS further states that “Congress may consider whether to devote additional resources to FDA and the U.S. Department of Agriculture to ensure the safety and quality of the many different products already available in many state markets.”

This report highlights the fact that rescheduling is very likely to happen, and that Congress still has an important role in the unfolding changes to federal marijuana policy.


© 2025 Wilson Elser
National Law Review, Volume XIII, Number 261